GI
STLN

GAMMA Investing’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

GAMMA Investing’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342 Hold
63
– – ﹤0.01% 4033
2026
Q1 		$193 Sell
63
-97
-61% -$297 ﹤0.01% 4059
2025
Q4 		$570 Buy
+160
New +$593 ﹤0.01% 3896

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

GAMMA Investing's STLN Position: Q2 2026 in Review

GAMMA Investing held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q2 2026 at 63 shares worth $342. The position accounts for ﹤0.01% of the portfolio, ranked #4033.

GAMMA Investing first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. The position peaked at $570 in Q4 2025. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • GAMMA Investing held 63 shares of Starling Oncology Institute, Inc. Common Stock worth $342 as of Q2 2026.
  • GAMMA Investing left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4033 holding.
  • GAMMA Investing first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • GAMMA Investing's Starling Oncology Institute, Inc. Common Stock position peaked at $570 in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.